Enlivex Updates ATM Program, Confirms $2.5M Sales and Authorizes Up to $250M in Future Dilution
ENLV sits 55% above its 52-week low of $0.66.
Summary
Enlivex Ltd. updated its At-The-Market (ATM) sales agreement, confirming prior sales of $2.5 million and authorizing the sale of up to an additional $250 million in ordinary shares, representing significant potential future dilution.
Key Events · Financing and Capital Events · ENLV
-
Confirms Prior ATM Sales
The company reported selling 1,936,660 ordinary shares for an aggregate gross sales price of $2,513,111 through its At-The-Market program since November 24, 2025.
-
Authorizes Up to $250 Million in Future Sales
Enlivex is authorized to sell up to an additional $250,000,000 of ordinary shares through its At-The-Market program, representing a substantial potential for future dilution.
-
Updates Existing ATM Program
This filing updates an At-The-Market Sales Agreement established on November 24, 2025, and slightly reduces the total remaining authorized amount from the initial registration.
Analysis · ENLV · Life Sciences
This 424B3 filing updates Enlivex's At-The-Market (ATM) sales agreement, originally established on November 24, 2025. The company has already sold $2.5 million worth of ordinary shares through this program, representing a significant portion of its current market capitalization. While the total authorized amount for the ATM program has been slightly reduced from the initial registration, the company is still authorized to sell up to an additional $250 million in ordinary shares. This substantial authorization, exceeding the company's current market capitalization, creates a significant overhang on the stock due to the potential for extreme dilution. Investors should be aware of the ongoing capital raise and its potential impact on share value.
At the time of this filing, ENLV was trading at $1.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $242.1M. The 52-week trading range was $0.66 to $2.10. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.